Natalia Erenburg

Mrs. Natalia Erenburg

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Epilepsia
Verified
Journal Article
Open access
EBErez Berman
Erez Berman
NENatalia Erenburg
Natalia Erenburg
RBRon Beloosesky
Ron Beloosesky
SESara Eyal
Sara Eyal
Michal KovoMichal Kovo
Michal Kovo
Objective: In the absence of safety data in humans, the use of cannabidiol (CBD) is not recommended during pregnancy. Yet >50% of pregnancies in women with epilepsy are unintended, making fetal exposure to CBD possible. As a small‐molecule, highly lipid‐soluble drug, CBD is likely to be distributed into the placenta and cross it. To estimate the placental distribution profile of CBD and its potential short‐term placental effects, we conducted an ex vivo perfusion study in human placentas.Methods: Placentas were obtained from healthy women undergoing cesarean deliveries. Selected cotyledons were cannulated and perfused for 180 min with a CBD‐containing medium (250 ng/mL, .796 μmol·L−1; representative of a low therapeutic concentration; n = 8). CBD concentrations were determined at 180 min in the medium and placental tissue using liquid chromatography–tandem mass spectrometry. A customized gene panel array was used to analyze the expression of selected genes in the perfused placental cotyledons as well as in placentas perfused with 1000 ng/mL CBD (3.18 μmol·L−1; high therapeutic concentration; n = 8) and in those exposed to the vehicle.Results: CBD was sequestered in the placental tissue, exhibiting significant variability across samples (median = 5342 ng/g tissue, range = 1066–9351 ng/g tissue). CBD concentrations in the fetal compartment were one fifth of those measured in the maternal compartment (median = 59 ng/mL, range = 48–72 ng/mL vs. 280 = ng/mL, range = 159–388 ng/mL, respectively; p < .01). Placental gene expression was not significantly altered by CBD.Significance: The placenta acts as a depot compartment for CBD, slowing down its distribution to the fetus. This phenomenon might yield flatter but prolonged fetal CBD levels in vivo. The attenuated transplacental CBD transfer does not imply that its use by pregnant women is safe for the fetus. Only pregnancy registries and neurocognitive assessments would establish the risk of being antenatally exposed to CBD.

Verified
Journal Article
Open access
PDF file
NENatalia Erenburg
Natalia Erenburg
Professor EMILIO PERUCCA PERUCCAProfessor EMILIO PERUCCA PERUCCA
Professor EMILIO PERUCCA PERUCCA
JBJeff Bechard
Jeff Bechard
DDDube Dube
Dube Dube
NWNina Weishaupt
Nina Weishaupt
MBMeir Bialer
Meir Bialer
The aim of this study was to investigate the comparative antiseizure activity of the l-enantiomers of d,l-fenfluramine and d,l-norfenfluramine and to evaluate the relationship between their concentration in plasma and brain and anticonvulsant activity. d,l-Fenfluramine, d,l-norfenfluramine and their individual enantiomers were evaluated in the mouse maximal electroshock seizure (MES) test. d,l-Fenfluramine, d,l-norfenfluramine and their individual l-enantiomers were also assessed in the DBA/2 mouse audiogenic seizure model. All compounds were administered intraperitoneally. Brain and plasma concentrations of the test compounds in DBA/2 mice were quantified and correlated with anticonvulsant activity. In the MES test, fenfluramine, norfenfluramine and their enantiomers showed comparable anticonvulsant activity, with ED50 values between 5.1 and 14.8 mg/kg. In the audiogenic seizure model, l-norfenfluramine was 9 times more potent than d,l-fenfluramine and 15 times more potent than l-fenfluramine based on ED50 (1.2 vs. 10.2 and 17.7 mg/kg, respectively). Brain concentrations of all compounds were about 20-fold higher than in plasma. Based on brain EC50 values, l-norfenfluramine was 7 times more potent than d,l-fenfluramine and 13 times more potent than l-fenfluramine (1940 vs. 13,200 and 25,400 ng/g, respectively). EC50 values for metabolically formed d,l-norfenfluramine and l-norfenfluramine were similar to brain EC50 values of the same compounds administered as such, suggesting that, in the audiogenic seizure model, the metabolites were responsible for the antiseizure activity of the parent compounds. Because of the evidence linking d-norfenfluramine to d,l-fenfluramine to cardiovascular and metabolic adverse effects, their l-enantiomers could potentially be safer follow-up compounds to d,l-fenfluramine. We found that, in the models tested, the activity of l-fenfluramine and l-norfenfluramine was comparable to that of the corresponding racemates. Based on the results in DBA/2 mice and other considerations, l-norfenfluramine appears to be a particularly attractive candidate for further evaluation as a novel, enantiomerically pure antiseizure medication.

15 December 2023 in Epilepsia
Verified
Journal Article
Closed access
NENatalia Erenburg
Natalia Erenburg
RHRoa'a Hamed
Roa'a Hamed
CSChanan Shaul
Chanan Shaul
DBDinorah Barasch
Dinorah Barasch
Professor EMILIO PERUCCA PERUCCAProfessor EMILIO PERUCCA PERUCCA
Professor EMILIO PERUCCA PERUCCA
MBMeir Bialer
Meir Bialer

Verified
Journal Article
Open access
PDF file
ROReem Odi
Reem Odi
DBDavid Bibi
David Bibi
BSBella Shusterman
Bella Shusterman
NENatalia Erenburg
Natalia Erenburg
CSChanan Shaul
Chanan Shaul
MBMeir Bialer
Meir Bialer
We recently reported a new class of carbamate derivatives as anticonvulsants. Among these, 3-methylpentyl(4-sulfamoylphenyl)carbamate (MSPC) stood out as the most potent compound with ED50 values of 13 mg/kg (i.p.) and 28 mg/kg (p.o.) in the rat maximal electroshock test (MES). 3-Methylpropyl(4-sulfamoylphenyl)carbamate (MBPC), reported and characterized here, is an MSPC analogous compound with two less aliphatic carbon atoms in its structure. As both MSPC and MBPC are chiral compounds, here, we studied the carbonic anhydrase inhibitory and anticonvulsant action of both MBPC enantiomers in comparison to those of MSPC as well as their pharmacokinetic properties. Racemic-MBPC and its enantiomers showed anticonvulsant activity in the rat maximal electroshock (MES) test with ED50 values in the range of 19–39 mg/kg. (R)-MBPC had a 65% higher clearance than its enantiomer and, consequently, a lower plasma exposure (AUC) than (S)-MSBC and racemic-MSBC. Nevertheless, (S)-MBPC had a slightly better brain permeability than (R)-MBPC with a brain-to-plasma (AUC) ratio of 1.32 (S-enantiomer), 1.49 (racemate), and 1.27 (R-enantiomer). This may contribute to its better anticonvulsant-ED50 value. The clearance of MBPC enantiomers was more enantioselective than the brain permeability and MES-ED50 values, suggesting that their anticonvulsant activity might be due to multiple mechanisms of action.

17 July 2025 in Epilepsia
Verified
Journal Article
Open access
YSYara Sheeni
Yara Sheeni
NENatalia Erenburg
Natalia Erenburg
DBDinorah Barasch
Dinorah Barasch
Tawfeeq Shekh-AhmadTawfeeq Shekh-Ahmad
Tawfeeq Shekh-Ahmad
Professor EMILIO PERUCCA PERUCCAProfessor EMILIO PERUCCA PERUCCA
Professor EMILIO PERUCCA PERUCCA
MBMeir Bialer
Meir Bialer
Objective: The in vivo effects of fenfluramine result from the combined actions of four active molecular entities ( l‐ fenfluramine, d‐ fenfluramine, and the corresponding enantiomers of the primary metabolite norfenfluramine). Each of these compounds has different properties, with cardiovascular toxicity risk being ascribed primarily to the d ‐enantiomers. To determine whether l ‐fenfluramine or l ‐norfenfluramine is a better candidate for development as an enantiomerically pure antiseizure medication, we investigated dose–response and brain/plasma concentration–response relationships for each of the four individual enantiomers in mice. Methods: Antiseizure activity was evaluated in the maximal electroshock (MES) model at the time of peak effect. Neurotoxicity was assessed by determining minimal motor impairment (MMI) in the rotarod test. Median effective dose (ED 50 ), median toxic dose (TD 50 ), median effective concentration (EC 50 ), and median toxic concentration (TC 50 ) in plasma and brain were estimated from dose– and concentration–response curves after administration of each individual enantiomer. Protective indexes (PIs) were estimated based on dose (TD 50 /ED 50 ) and plasma/brain concentrations (TC 50 /EC 50 ). Results: The four enantiomers differed in antiseizure potency and neurotoxic activity. d‐ Norfenfluramine had the highest potency, but it also had the highest toxicity and the lowest PI. Differences in antiseizure potency and toxicity estimated from plasma and brain concentrations were more prominent than those estimated based on dose. l‐ Fenfluramine had greater potency than d‐ fenfluramine and l‐ norfenfluramine, and was overall the compound with the highest PI (6.3 based on dose, 41.6 based on plasma concentrations, and 39.2 based on brain concentrations). Significance: These findings are relevant in determining which enantiomer is most suitable for clinical development as a stereoselectively pure follow‐up compound to the marketed racemic fenfluramine, and indicate that l ‐fenfluramine has superior antiseizure activity over l ‐norfenfluramine in the MES model. This study also illustrates the limitations of relying solely on dose–response curves, and the added value of assessing concentration–response relationships.

9 August 2025 in Epilepsia
Verified
Journal Article
Open access
EBErez Berman
Erez Berman
GPGali Pariente
Gali Pariente
NENatalia Erenburg
Natalia Erenburg
RHRoa'a Hamed
Roa'a Hamed
CLCecilie Johannessen Landmark
Cecilie Johannessen Landmark
SESara Eyal
Sara Eyal
Objective: In women with epilepsy who are treated with antiseizure medications (ASMs), folate concentrations in maternal serum may not be a good indicator of fetal folate supply, because ASMs can interfere with folate handling by the placenta. We aimed to assess the transplacental folate transfer at birth in persons with epilepsy in comparison to controls with no known epilepsy and identify factors affecting it. Methods: This was a cross‐sectional, two‐center study, involving 22 pregnant women with epilepsy treated with ASMs, 10 nontreated pregnant women with epilepsy, and 19 control pregnant individuals with no known epilepsy. Maternal venous blood and umbilical cord blood samples were collected at delivery. Folate concentrations were measured using a validated chemiluminescence assay. ASM concentrations were analyzed in serum and umbilical cord blood. Results: Maternal and neonatal characteristics were generally comparable across the study groups, but cesarian sections were more frequent among controls ( p < .001). Folate concentrations in maternal serum were lower than recommended levels in nine of 26 (35%) of women with epilepsy and eight of 19 (42%) controls. Median cord/maternal serum folate ratios were 1.51 (95% confidence interval [CI] = .92–6.35; n = 17) in women with epilepsy treated with ASMs and 2.02 (95% CI = 1.69–3.71; n = 19) in controls. In women with epilepsy, placental folate transfer was saturable (Cmax = 131.1 ng/mL, 95% CI = 96.4–190.5 ng/mL; Michaelis‐Menten constant, Km = 32.6 ng/mL, 95% CI = 12.5–76.9 ng/mL; adjusted R 2 = .70). Predictability of cord values improved upon exclusion of preterm births (Cmax = 125.2 ng/mL, 95% CI = 97.4–164.7 ng/mL; Km =41.1 ng/mL, 95% CI = 22.4–71.1 ng/mL; adjusted R 2 = .78). Significance: Folate delivery to the fetus during late pregnancy is primarily explained by its concentrations in maternal circulation. In persons with epilepsy, it may be saturable. The frequent apparent folate deficiency observed in our cohort highlights the importance of folate supplementation and monitoring of its levels in maternal circulation throughout pregnancy.